Sponsored genetic testing programs can run afoul of federal laws, including the FCA and AKS, if not designed correctly. Experts at Morrison Foerster share best practices for compliance.
- A CEO With A General Counsel's Perspective
- Interchangeability In Leadership: A Career Built On Versatility
- An Updated View of The Federal Segment: DHA Formulary Management
- FCPA Enforcement Paused At DOJ, But Biopharma Shouldn't Pause Compliance
- A Guide To Successful Product Launches For Small And Midsized Biotechs
- Where Are They Now? Tarsus Pharmaceuticals
- Tax Planning For Life Sciences Amid Shifting Policies
- Day One Bio Aims To Shorten The Time Gap On Cancer Treatments For Kids
COMPANIES TO WATCH
-
Companies To Watch: Senti Bio
Senti Bio aims to improve cancer therapeutics with customizable gene circuits, or multi-gene constructs capable of identifying cancer targets on both healthy and diseased cells.
-
Terns Pharmaceuticals aims to improve upon currently marketed therapies in CML and obesity, using internally discovered small molecules.
-
Spinogenix is using small molecule drugs to regenerate synapses in patients with ALS, Alzheimer's disease, schizophrenia, glaucoma, and Fragile X syndrome.
-
Aurion Biotech is developing what could become the first allogeneic combination cell therapy for the treatment of corneal endothelial diseases.
WHERE ARE THEY NOW
-
Where Are They Now? Tarsus Pharmaceuticals
Tarsus Pharmaceuticals is making a splash with Xdemvy, an eye drop that kills the demodex mites that cause inflammation and irritation in the eyelid. A new consumer DTC campaign, potential global approvals, and a new indication in the clinic could turn Xdemvy into a blockbuster drug.
-
Where Are They Now? Teva Pharmaceuticals
Teva Pharmaceuticals "pivot to growth" strategy under CEO Richard Francis aims to use a combination of biosimilars, generics, and branded drugs to set the company back on track, or back to the future.
-
Where Are They Now? Ironwood Pharmaceuticals
Ironwood Pharmaceuticals is a smaller company than it was in 2016, when Life Science Leader wrote a feature article about its founder and mission. But Peter Hecht, Ironwood's former CEO, who now leads Tisento Therapeutics, has practiced what he preached.
NEWSLETTER ARCHIVE
- 03.14.25 -- A CEO With A General Counsel's Perspective
- 03.13.25 -- Optimize Your High Concentration Biologic Production Process
- 03.12.25 -- Interchangeability In Leadership: A Career Built On Versatility
- 03.10.25 -- An Updated View of The Federal Segment: DHA Formulary Management
- 03.10.25 -- Patient Engagement Through Community Research
